Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer.
Tri-potassium di-citrato bismuthate is a complex bismuth salt stable in colloidal form advocated for the treatment of peptic ulcer. Preliminary placebo-controlled trials in small numbers of ambulant patients with endoscopically proven peptic ulcer, strongly suggest that the compound accelerates the rate of healing of gastric and duodenal ulcer within 4 weeks of treatment. However, trials involving larger numbers of patients followed-up for longer periods are required before a clear verdict on the efficacy of tripotassium di-citrato bismuthate in gastric and duodenal ulcer can be given. There are no reliable data on the effect of the drug on ulcer recurrence rate. Side-effects are negligible and the drug could become an important therapeutic agent in peptic ulcer therapy if results of further study are conclusive. The drug causes dark discolouration of the stools and this should be borne in mind when considering the possibility of the presence of intestinal bleeding.
D000818:Animals; D000897:Anti-Ulcer Agents; D001729:Bismuth / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004381:Duodenal Ulcer / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D010437:Peptic Ulcer / Q000188:drug therapy*; D051381:Rats; D013276:Stomach Ulcer / Q000188:drug therapy
D000897:Anti-Ulcer Agents; D001729:Bismuth